Patents by Inventor Klaus Maleck

Klaus Maleck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for breeding disease resistance into plants
    Patent number: 6107544
    Abstract: Methods are provided for selecting parental plants exhibiting disease resistance and for using these plants in breeding programs. In one method of the invention, constitutive immunity (cim) mutants are screened for either resistance to a pathogen of interest or for the expression of systemic acquired resistance (SAR) genes. Such mutants having the desired traits or expressing the desired genes are then used in breeding programs. Parent plants can also be selected based on the constitutive expression of SAR genes. These mutants are phenotypically normal yet exhibit a significant level of disease resistance. Also disclosed are lesion-simulating-disease (lsd) mutants having a lesion mimic phenotype that also express SAR genes and exhibit disease resistance. Further disclosed are non-inducible immunity (nim) mutants that do not express SAR genes, even when induced by a pathogen. Methods of use for these mutants are also disclosed.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: August 22, 2000
    Assignee: Novartis Finance Corporation
    Inventors: John Andrew Ryals, Scott Joseph Uknes, Eric Russell Ward, Terrence Patrick Delaney, Kay Ann Lawton, Kristianna Baldwin Weymann, Henry-York Steiner, Klaus Maleck
  • Method for selecting disease resistant mutant plants
    Patent number: 6057490
    Abstract: Methods are provided for selecting parental plants exhibiting disease resistance and for using these plants in breeding programs. In one method of the invention, constitutive immunity (cim) mutants are screened for either resistance to a pathogen of interest or for the expression of systemic acquired resistance (SAR) genes. Such mutants having the desired traits or expressing the desired genes are then used in breeding programs. Parent plants can also be selected based on the constitutive expression of SAR genes. These mutants are phenotypically normal yet exhibit a significant level of disease resistance. Also disclosed are lesion-simulating-disease (lsd) mutants having a lesion mimic phenotype that also express SAR genes and exhibit disease resistance. Further disclosed are non-inducible immunity (nim) mutants that do not express SAR genes, even when induced by a pathogen. Methods of use for these mutants are also disclosed.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: May 2, 2000
    Assignee: Novartis Finance Corporation
    Inventors: John Andrew Ryals, Scott Joseph Uknes, Eric Russell Ward, Klaus Maleck